Form 4: National Health Investors SVP/Chief Transaction Officer, Gaines Kristin Sallee, Reports Acquisition of Shares and Stock Options
SEC Form 4
Kristin Sallee Gaines, SVP/Chief Transaction Officer of National Health Investors, reports the acquisition of 3,000 shares of common stock and multiple stock option grants.
Summary
- On February 23, 2024, Kristin Sallee Gaines, SVP/Chief Transaction Officer of National Health Investors Inc. (NHI), reported acquiring 3,000 shares of common stock at $0 and multiple stock options.
- The acquired shares are restricted stock that vest 20% annually, starting February 23, 2025.
- Gaines also acquired options to buy common stock at a price of $57.76, with varying exercisable dates starting from February 23, 2024, to February 23, 2026, and all expiring on February 23, 2029.
- Following the reported transactions, Gaines beneficially owns 51,609 shares of common stock.
- Gaines also holds various other stock options granted in previous years (2020, 2021, 2022, and 2023) with exercise prices ranging from $53.41 to $90.79 and expiration dates in 2025, 2026, 2027 and 2028.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option transactions by an executive. The acquisition of shares could be interpreted as a positive signal, but it's part of a compensation package.
Positives
- The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock and options.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock to align management's interests with those of shareholders.
- The vesting schedules and exercise prices of the options appear to be standard practice for incentivizing long-term performance.
- Comparing the size of the stock option grants and restricted stock awards to those of executives at comparable REITs (e.g., Welltower, Ventas, Healthpeak Properties) would provide further context.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| 02/21/2020 | Date of grant for some stock options with an exercise price of $90.79 and expiration on 02/21/2025. |
| 02/25/2021 | Date of grant for some stock options with an exercise price of $69.2 and expiration on 02/25/2026. |
| 02/25/2022 | Date of grant for some stock options with an exercise price of $53.41 and expiration on 02/25/2027. |
| 02/24/2023 | Date of grant for some stock options with an exercise price of $54.73 and expiration on 02/24/2028. |
| 02/23/2024 | Date of transaction: acquisition of common stock and stock options. |
| 02/23/2025 | First vesting date (20%) for the restricted stock acquired on 02/23/2024. |
| 02/23/2029 | Expiration date for the stock options acquired on 02/23/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.